Active DMD Clinical Studies

Overview of ongoing Duchenne clinical trials grouped by therapeutic approach. Completed and terminated studies are not listed.

Back to trial search

Gene Therapy

Gene Therapy active clinical studies
CompanyDrugPhaseVariant RequirementStatusLocationsClinical Trial
Sarepta TherapeuticsSRP-9001-402 (Delandistrogene Moxeparvovec) ELEVIDYSPhase 4Has an established clinical diagnosis of DMD based on documentation of clinical findings and prior confirmatory genetic testing using a clinical diagnostic genetic test.Not Yet RecruitingUnited StatesNCT07542314
Sarepta TherapeuticsSRP-9001-303 (Delandistrogene Moxeparvovec) ELEVIDYSPhase 3Definitive diagnosis of DMD based on documented clinical findings and prior genetic testing.Active, Not RecruitingUnited States, Australia, Belgium, Canada, Germany, Hong Kong, Israel, Italy, Japan, South Korea, Spain, Sweden, Taiwan, United KingdomNCT05881408
Solid BiosciencesSGT-003Phase 3Established clinical diagnosis of DMD and documented DMD gene mutation predictive of DMD phenotype.Actively RecruitingUnited States, Canada, AustraliaNCT07160634
REGENXBIORGX-202Phase 2/3DMD gene mutation in exons 18 and above, and a clinical picture consistent with typical DMD with the exception of a participant (Cohort 1b) with DMD gene mutation in exons 12-17.Actively RecruitingUnited States, CanadaNCT05693142
GENERIUMGNR-097Phase 2Ambulatory boys aged 4-9 years with a documented diagnosis of DMD and clinical manifestations of the disease.Actively RecruitingRussia, BelarusNCT07673809
Hoffmann-La RocheENVOL (Delandistrogene Moxeparvovec) ELEVIDYSPhase 2Has a definitive diagnosis of DMD prior to screening based on documentation of clinical findings and prior confirmatory genetic testing using a clinical diagnostic genetic testActive, Not RecruitingBelgium, France, Germany, Italy, Spain, United KingdomNCT06128564
Solid BiosciencesSGT-003Phase 1/2Established clinical diagnosis of DMD and documented dystrophin gene mutation predictive of DMD phenotype confirmed by Sponsor genetic testing. In cases where a genotype may be predictive of residual dystrophin production and/or a clear clinical diagnosis of DMD cannot be made (e.g., due to age), evaluation of dystrophin levels in baseline muscle biopsies may be required to determine eligibility under this criterion.Actively RecruitingUnited States, Canada, Italy, United KingdomNCT06138639
Solid BiosciencesSGT-001Phase 1/2Established clinical diagnosis of DMD and documented dystrophin gene mutation predictive of DMD phenotype.Active, Not RecruitingUnited StatesNCT03368742
Insmed Gene Therapy LLCINS1201Phase 1Has a definitive diagnosis of DMD prior to Screening or as part of Screening based on genetic testing. Note that participants who rescreen do not have to repeat genetic testing for the diagnosis of DMD if one is already on file. Genetic reports must describe a frameshift deletion, frameshift duplication, premature stop ("nonsense"), canonical splice site mutation, or other pathogenic variant in the DMD gene fully contained between exons 18 to 58 (inclusive) that is expected to lead to absence of a functional dystrophin protein (mutations in exons 1-17 or 59-71 are therefore not permitted).Actively RecruitingUnited StatesNCT06817382
Sarepta TherapeuticsSRP-9001-103 (Delandistrogene Moxeparvovec) ELEVIDYSPhase 1For Cohorts 1-8: Has a definitive diagnosis of DMD based on documented clinical findings and prior genetic testing.Actively RecruitingUnited StatesNCT04626674
Shanghai Jiao Tong University School of MedicineBBM-D101Early Phase 1Genetically confirmed diagnosis of DMD.Actively RecruitingChinaNCT06641895
Shanghai Siponuoyin Biotechnology Co LtdSPOT-mRNA03 (SPOT-03)Early Phase 1Boys aged ≥ 2 years to < 8 years and capable of walking independently for at least 10 meters.Actively RecruitingChinaNCT07188012
Sarepta TherapeuticsSRP-9001-305 (Delandistrogene Moxeparvovec) ELEVIDYSInterventionalThe purpose of this study is to provide a single clinical study with a uniform approach to monitoring long-term safety and efficacy in participants who received delandistrogene moxeparvovec in a previous clinical study. No study drug will be administered as part of this study.Enrolling by InvitationUnited States, Belgium, Germany, Hong Kong, Italy, Japan, Spain, Taiwan, United KingdomNCT05967351
REGENXBIORGX-202ObservationalHas an established clinical diagnosis of DMD based on documentation of clinical findings and prior confirmatory genetic testing using a clinical diagnostic genetic test.Actively RecruitingUnited StatesNCT05683379
Sarepta TherapeuticsSRP-9001-401 (Delandistrogene Moxeparvovec) ELEVIDYSObservationalHas an established clinical diagnosis of DMD based on documentation of clinical findings and prior confirmatory genetic testing using a clinical diagnostic genetic test.Enrolling by InvitationUnited StatesNCT06270719

Exon Skipping

Exon Skipping active clinical studies
CompanyDrugPhaseVariant RequirementStatusLocationsClinical Trial
NS PharmaBrogidirsen NS-089/​NCNP-02-201Phase 2Confirmed DMD mutation(s) in the dystrophin gene that is amenable to skipping of exon 44 to restore the dystrophin mRNA reading frame.Actively RecruitingUnited States, Australia, Canada, Japan, New Zealand, South Korea, TurkeyNCT05996003
NS PharmaNS-050/NCNP-03 Meteor50Phase 1/2Confirmed DMD exon deletion in the dystrophin gene that is amenable to skipping of exon 50 to restore the dystrophin mRNA reading frame.Active, Not RecruitingUnited States, Canada, Japan, South Korea, TurkeyNCT06053814